Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06770933 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
A Phase 2 study of Diabetic Retinopathy and NPDR - Non Proliferative Diabetic Retinopathy, sponsored by Vantage Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT06770933 is a Phase 2 study of Diabetic Retinopathy and NPDR - Non Proliferative Diabetic Retinopathy that is actively recruiting participants, run by Vantage Biosciences. The registered enrollment target is 100 participants, below the 1,675-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06770933, a Phase 2 study of Diabetic Retinopathy and NPDR - Non Proliferative Diabetic Retinopathy, is actively recruiting participants, sponsored by Vantage Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatment for Diabetic Retinopathy of Non-Proliferative Type (NPDR). The primary objective of the study is to evaluate the efficacy of daily oral doses of VX-01 versus placebo following 52 weeks of treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VX-01
Study Locations (20)
New South Wales
- Eye Clinic Albury Wodonga - Albury
- Retina And Eye Consultants Hurstville - Hurstville
- Marsden Eye Specialists - Parramatta
- Sydney Eye Hospital - Sydney
- Sydney Retina Clinic - Sydney
- Sydney West Retina - Westmead
California
- Retina-Vitreous Associates Medical Group - Beverly Hills
- Stanford Byers Eye Institute - Palo Alto
- California Retina Consultants- Santa Barbara - Santa Barbara
Other
- Prince of Wales Hospital The Chinese University of Hong Kong - Shatin
- HKU Eye Centre - Wong Chuk Hang
Florida
- Florida Retina Institute - Jacksonville Southside - Jacksonville
Illinois
- Retina Associates - Elmhurst
Maryland
- Cumberland Valley Retina Consultants - Hagerstown
Pennsylvania
- Erie Retina Research - Erie
Virginia
- Piedmont Eye Center - Lynchburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-02-11 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06770933
The ClinicalTrials.gov registry entry for NCT06770933 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,675-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (94% lower). The listed sponsor is Vantage Biosciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetic Retinopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06770933 reports 20 study locations spanning 12 distinct geographic areas - top geographies include New South Wales, California, Other.
Frequently Asked Questions
What is clinical trial NCT06770933 about?
NCT06770933 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01". The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatment for Diabetic Retinopathy of Non-Proliferative Type (NPDR). The primary objective of the study is to evaluate the efficacy of daily oral doses of VX-...
What is the current status of trial NCT06770933?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-02-11. Estimated completion is 2027-03.
What conditions does trial NCT06770933 study?
This clinical trial studies the following conditions: Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy.
What interventions are being tested in trial NCT06770933?
The interventions under investigation include: Placebo (DRUG), VX-01 (DRUG).
Who is sponsoring clinical trial NCT06770933?
This trial is sponsored by Vantage Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06770933 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Maryland, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
RECRUITING · Phase 2
-
Sleep, Diabetic Retinopathy and Melatonin
RECRUITING · Phase 2
-
4D-150 in Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 2
-
A Study of PER-001 in Participants With Diabetic Retinopathy
ACTIVE NOT RECRUITING · Phase 2
-
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
COMPLETED · Phase 2
-
Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema
COMPLETED · Phase 2
Explore more on PlainTrial
Diabetic Retinopathy
All registered trials for this condition
NPDR - Non Proliferative Diabetic Retinopathy
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.